Avelumab Biosimilar - Research Grade

Human

PD-L1

1.0 - 5.0 mg/ml

Human IgG1 lambda

Humanized

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Avelumab.

Blue ice

Programmed death-ligand 1 (PD-L1) is an immune checkpoint ligand that suppresses T-cell responses and a central target in cancer immunology research. This research-grade anti-human PD-L1 recombinant monoclonal antibody is an unconjugated, non-therapeutic analog of avelumab, built around the PD-L1 target as a human IgG1-lambda for research use only. Produced to in vivo standards as an ultra-pure, low-endotoxin preparation, it is supplied in scalable milligram to gram quantities for high-throughput and bulk laboratories. It serves as a control and active reagent across preclinical work, including checkpoint-blockade assays, in vitro screening, in vivo tumour immunology models, and ADCC studies.

Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, PDL-1

Q9NZQ7

ICH3001-100ml ICH3002-100ml ICH3003-100ml

https://www.imgt.org/mAb-DB/